Earnings ·
Upstream Bio reported second quarter 2026 financial results and clinical updates
UPBUpstream Bio, Inc.
Upstream Bio reported second quarter 2026 financial results and clinical updates. The company had cash, cash equivalents, and short-term investments of $261.3 million as of June 30, 2026, sufficient to fund operations through 2027. R&D expenses were $36.1 million and G&A expenses were $7.1 million, resulting in a net loss of $39.7 million compared to a $40.0 million loss in the prior year period. Clinically, Upstream Bio remains on track to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027 following End-of-Phase 2 FDA interactions. Enrollment was completed in the Phase 2 VENTURE trial in COPD with 481 participants, with data expected in H2 2027. Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases.